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license (http://creativecommons.org/Summary Background/Objective: Despite recent progress in regeneration medicine, the
repair of large bone defects due to trauma, inflammation and tumor surgery remains a major
clinical challenge. This study was designed to produce large amounts of viable bone graft ma-
terials in a novel perfusion bioreactor to promote bone formation.
Methods: Cylindrical defects were created bilaterally in the distal femurs of sheep, and tita-
nium implants were inserted. The concentric gap around the implants was randomly filled
either with allograft, granules, granules with bone marrow aspirate (BMA) or bioreactor acti-
vated granule (BAG). The viable BAG consisted of autologous bone marrow stromal cells
(BMSCs) seeded upon porous scaffold granules incubated in a 3D perfusion bioreactor for 2
weeks prior to surgery. 6 weeks after, the bone formation and early implant fixation were as-
sessed by means of micro-CT, histomorphometry, and mechanical test.
Results: Microarchitectural analysis revealed that bone volume fraction and trabecular thick-
ness in the allograft were not statistically different than those (combination of new bone and
residue of granule) in the other 3 groups. The structure of the allograft group was typically
plate-like, while the other 3 groups were combination of plate and rod. Histomorphometry
showed that allograft induced significantly more bone and less fibrous tissue in the concentric
gap than the other 3 granule groups, while the bone ingrowth to implant porous surface wasc Research Laboratory, Department of Orthopaedic Surgery and Traumatology, Odense University
-5000, Odense C, Denmark.
(M. Ding).
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Bioreactor activated granules for implant fixation 39not different. No significant differences among the groups were found regarding early implant
mechanical fixation.
Conclusion: In conclusion, despite nice bone formation and implant fixation in all groups,
bioreactor activated graft material did not convincingly induce early implant fixation similar
to allograft, and neither bioreactor nor by adding BMA credited additional benefit for bone for-
mation in this model.
Copyrightª 2015, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The early bone ingrowth to porous surface of implants in-
creases primary implant fixation and reduces the risk of
implant failure [1]. Osseointegration is influenced by the
primary mechanical stability and secondary biological sta-
bility after bone remodelling of the implant in the bone.
Thereby, early bone formation and apposition is essential
for secondary stability [2].
Despite recent progress in regeneration medicine, the
repair of large bone defects due to trauma, inflammation,
and tumour surgery remains a major clinical challenge.
Large animal models have been developed to test bone
repair by tissue engineering approaches that combines the
principles of engineering and life sciences to overcome
drawbacks of traditional bone regeneration techniques
used in orthopaedics [3]. These new techniques are inten-
ded to develop the tissue-engineered constructs with
similar structural and mechanical characteristics of natural
bone [4]. In general, an advantage in the bone regeneration
in large defect has often been reported when scaffolds
were seeded with bone marrow derived stromal cells
(BMSCs) [5].
Consequently, bioreactor is introduced. This device en-
ables a closely monitored and tightly controlled environ-
ment to allow biological and biochemical processes. Bone
tissue engineering consists of static cultures, in which bone
cells are seeded on a 3-dimensional (3D) scaffold and
placed in a well-plate for a certain period of time. This
culture strategy leads to significant drawbacks that the
cells tended to accumulate at the periphery of the scaffold
leading to poor nutrient and waste exchange in the centre
of the scaffold [6]. Furthermore, cell necrosis could also be
formed in the centre of the scaffold. Dynamic bioreactors
such as perfusion bioreactors might overcome such prob-
lems in cell culture.
A perfusion bioreactor is developed and designed to
mimic the microscopic mechanical loading of bone in vivo
[7]. Perfusion bioreactor systems automatically pump cul-
ture medium through the interconnected pores of scaffold
that is press-fitted into a culture chamber [8e10]. With flow
perfusion, the mass transfer is enhanced at the interior of
the 3D scaffold and shear forces are applied to the cultured
cells. Compared with other bioreactor systems, a perfusion
bioreactor increases mass transport leading to improved
distribution of extracellular matrix throughout the 3D
scaffold, increased cell number, enhanced expression of
the osteogenic phenotype, and improved mineralizedextracellular matrix deposition [9,11,12]. It is worth noting
that only the perfusion bioreactor is able to eliminate
diffusion limitations inside a scaffold, although dynamic
bioreactors can overcome diffusion limitations at the sur-
face of a scaffold [9,13]. Hence, the perfusion bioreactor
seems to be a very useful dynamic culture technique for
bone tissue engineering [4,6], and is the current most
commonly used dynamic bioreactor [14].
This study was designed to produce viable bone graft
material for early fixation of titanium alloy implants to
bone defects. The procedures described and used aimed at
mimicking the possible future clinical setting, where
autologous BMSCs were harvested and implanted with a
biomaterial around a critical defect created in association
with a revision of a total joint arthroplasty (fluidised bed
concept). We hypothesised that filling with the bioreactor
activated graft material (BAG) in a 2 mm defect in sheep
bone would result in ingrowth and bone formation compa-
rable to allograft.
Materials and methods
Study design
This study used a well-validated bilateral implant-gap
defect model that has been described in detail previously
[15,16]. Eight sheep were included based on sample size
calculation and our previous experience. Cylindrical de-
fects were created laterally and medially in the bilateral
distal femoral condyles of each sheep. This allowed bilat-
eral insertion (press fit) of titanium alloy implants extra-
articularly in the distal femurs; thus, four implants per
sheep. The concentric defect around the inserted titanium
alloy implant was filled with one of the four materials: (1)
allograft serving as control; (2) granule; (3) granules incu-
bated with fresh autologous bone marrow aspirate (BMA);
or (4) granules incubated for 2 weeks in a bioreactor with
autologous BMSCs. The filling materials were alternated
between insertion holes in order to avoid any site depen-
dent differences. This randomisation allowed all four ma-
terials to be implanted medially or laterally within the
same sheep.
Animals and bone marrow aspiration
This study was approved by the Danish Animal Experiments
and Inspectorates (no. 2008/561-1544), and all animal
40 M. Ding et al.experiments were performed in accordance with the ani-
mal research guidelines. Eight skeletally mature female
ewes (mean age 4 y) of Merino/Gotland mixed breed were
used. The sheep were not bred for experimental purposes,
but bought for the experiment from a local farmer. Mean
weight was 77.9  11.0 kg. The animals were housed in
facilities provided by the Biomedical Laboratory at the
University of Southern Denmark, Odense, Denmark. A
limited amount of compound feed was provided together
with free access to water, straw, and hay. All efforts were
made to minimise animal suffering.
Bonemarrow (4 5mL) was aspirated from the iliac crest
of the eight anaesthetised sheep. Xylazine (0.01 mL/kg
Rompun Vet, Bayer, Leverkusen, Germany) was given, fol-
lowed by propofol (1 mg/kg; Rapinovet, Schering-Plough,
Ballerup, Denmark). Two millilitres of lidocaine (Amgros,
Copenhagen, Denmark) was applied to the posterior iliac
crests prior to aspiration for local anaesthesia. The aspirates
were immediately transferred to Falcon tubes containing
Gibco’s a-minimal essential medium (Gibco’s a-MEMþ,
Invitrogen, Taastrup, Denmark) with 1 mL 5000 I.U./mL
heparine (Nycomed, Copenhagen, Denmark). On indication,
2 mL of 0.03 mg/mL buprenorphine (Temgesic, Schering-
Plough, Ballerup, Denmark) was given intramuscularly.
Isolation of mononuclear cells
Mononuclear cells were isolated using density gradient
centrifugation through a Histopaque gradient (Sigma-
Aldrich, Brøndby, Denmark). The total amounts of isolated
cells from each sheep were resuspended in 22 mL of fresh
a-MEMþ before injection into a perfusion bioreactor (Mil-
lenium Biologix AG, Zurich, Switzerland).
Fibroblastic colony forming units assay
The osteogenic potential of the mononuclear cells were
evaluated by a fibroblastic colony forming unit (CFU-f)
assay according to previous studies [8,17]. The fractions of
clonogenic fibroblastic cells in the total amount of isolated
mononuclear cells were determined using a CFU-f assay.
From the isolated cells, 105 cells were aspirated and
resuspended in 15 mL a-MEMþ before plating in T-80 flasks.
Then, the flasks were incubated until the cells reached
confluence or colonies were visible (at 2 weeks). Incubation
media was changed weekly, thereby washing off any un-
attached cells, and thus keeping only living cells of the
mesenchymal lineage. Following incubation, the media was
aspirated and the cells were fixed in 4% buffered formalin
before staining with crystal violet for approximately 30
minutes. Crystal violet was aspirated and the CFU-f was
counted [8].
Perfusion bioreactor
The perfusion bioreactor was developed by Millenium Bio-
logix AG (Basel, Switzerland) as part of the European
project “AUTOBONE”, the Sixth European Framework Pro-
gram (Project “AUTOBONE”, Grant No. NMP3-CT-2003-
505711). The 3D perfusion bioreactor system is described in
detail in a recent publication [18]. The cylindrical scaffoldchambers (diameter Z 0.9 cm) were modified for this
study; thus containing 1 mL of scaffold granules.
Scaffold granules within the chamber were perfused
twice with 22 mL a-MEMþ 2 hours prior to injection of
isolated cells (“washing” step). The cell was resuspended in
22 mL of fresh a-MEMþ before injection into the perfusion
bioreactor. The bioreactor ran a “seeding” step for 4 days
with a perfusion flow of 40 mL/min. Hereafter, fresh a-
MEMþ supplemented with 10nM dexamethasone, 0.1mM L-
ascorbic-acid-2-phosphate, and 5 ng/mL fibroblast growth
factor-2 were injected into the perfusion bioreactor every
3rd or 4th day, starting 4 days after bioreactor incubation
was initiated [18,19]. After the initiation phase, the
perfusion flow was reduced to 4 mL/min for the remaining
incubation time. Throughout the 2 weeks incubation
period, the perfusion bioreactor was placed inside an
incubator (37C, 5% CO2) [18].Titanium alloy implants
A total of 32 plasma-sprayed, porous titanium alloy im-
plants were used (90% titanium, 6% aluminium, 4% vana-
dium; kindly donated by Biomet, Warsaw, IN, USA). The
implants were cylindrical with a height of 10 mm and an
inner column diameter of 6 mm. Attached with a footplate
and top washer, both 10 mm in diameter; thus resulting in a
circumferential gap of 0.5 mL. The porous surface had a
mean porosity of 44% and a mean pore diameter of 480 mm
(as specified by the manufacturer) [8].Graft materials
Allograft
Morselized allograft (Ø 200e600 mm) was prepared from
bone harvesting from the distal femurs and proximal tibias
of a skeletally mature healthy female sheep at least 6
months prior to surgery. Sterile vials containing 1 mL allo-
graft were kept at 80C until the day of surgery.
Scaffold granules
Scaffold granules (Ø 1000e1500 mm, 88 % porosity), con-
sisting of hydroxyapatite (HA) 70% and b-tricalcium-phos-
phate (b-TCP) 30%, were supplied by the Danish
Technological Institute. The organic polymer (PDLLA)-rein-
forced HA/b-TCP contained 88% inorganic ceramic (70% HA
and 30% b-TCP) and 12% PDLLA by weight. An ultra-thin layer
of PDLLA was infiltrated on the surface of the pores, and
kept intermicropore connections [20]. These granules were
coated with a polymer in order to increase the mechanical
strength of the newly formed bone [21]. The polymer was
[50% polylactic acid (D-PLA), 50% L-PLA] poly-lactic acid
(PDLLA) 12.5%, and its molecular weight was 308 kDa (Phu-
sis, Saint Ismier, France). The pore sizes were 300e700 mm,
and interconnecting pore sizes were 100e200 mm.
Scaffold granules with BMA
During surgery, 2 mL of freshly aspirated autologous BMA
was aspirated from the proximal tibia. The BMA was quickly
mixed with the scaffold granules in a sterile petri dish
before filling around the titanium alloy implant.
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The BAG was incubated for 2 weeks in the perfusion
bioreactor with autologous mononuclear cells as described
above. On the day of surgery, the bioreactor had finished
the 2 weeks incubation period, and the BAG material was
filled around the critical sized defect created in the distal
femur as described below.
Surgical procedure and implantation model
Surgical procedures were performed under general anaes-
thesia. The sheep were premedicated with xylazine
(10 mL/kg; Rompun Vet; Bayer) and intravenous injection
of propofol (1 mg/kg; Rapinovet; Schering-Plough) on
indication. A bolus injection of 2 mL 0.03 mg/mL bupre-
norphine (Temgesic; Schering-Plough) was given as pro-
phylactic analgesia. The sheep were intubated in order to
maintain general anaesthesia by inhalation of 2.0% iso-
flurane during surgery (Siesta Vet, Dameca, Denmark).
An implant-gap defect model was applied to the bilateral
distal femurs of all sheep. After shaving and disinfection of
the skin, the distal femur condyle was exposed by a lateral
incision. A guide K-wire was used perpendicularly to the
surface of the condyle, a central guide holewas drilled before
drilling a 12 mm deep cylindrical hole first with a sharp drill
then with a flat drill. The drill hole was rinsed with 20 mL
saline, and titanium alloy implants were press-fit inserted
into the cylindrical defects. The concentric gap (0.5 mL)
surrounding the titanium implant was filled with allograft,
scaffold granules, scaffold granules with fresh BMA, or BAG
material according to a randomised scheme. The gap was
closed with a top washer. The ligaments were tightly sutured
over the defect, and the wounds were closed with sutures in
three layers. The same procedure was repeated for the
medial side and for the opposite femur [22].
Three times daily 2.0 mL 0.03 mL/mg buprenorphine
(Temgesic; Schering-Plough), and once daily 9.0 mL
250 mg/mL ampicillin (Ampivet Vet, Boehringer Ingelheim,
Denmark) were given for 6e7 days postoperatively. The
sheep were allowed to move freely around, and most of the
sheep were already walking/standing 2 hours after surgery.
Six weeks after surgery, the sheep were euthanized with an
overdose of pentobarbital.
Preparation of bone specimens
The distal femurs were harvested and stored at 20C until
further processing. Soft tissues were carefully cleared off
the specimens, and the femur condyles were sawed in two
partsdlateral and medial on a continuing water irrigation
Exact diamond band saw (Apparatebau, GmbH, Germany).
The top washer was sawed off; hereafter, a second saw was
made to create a bone-implant specimen with a thickness
of 3.5 mm. These bone-implant specimens were immedi-
ately frozen and stored at 20C, before undergoing
microcomputed tomography (mCT) scanning and further
mechanical testing. The remaining part of the bone-
implant specimen was sawed to a thickness of 6 mm for
histomorphometry [8].
The latter 6 mm specimens were transferred to graded
ethanol (70e100%) containing basic fuchsin for dehydration.Following dehydration, the specimens were fixed in meth-
ylmetacrylate (Technovit 9100 NEW; Heraus Kulzer GmbH,
Germany). The vertical sectioning method was applied to
prepare 30 mm thick sections for histomorphometric ana-
lyses [23]. The sections were sawed on a custom-made
microtome (Instrumentmakerij, Medeja, The Netherlands),
and were counterstained with 2% light green for 2 minutes,
rinsed, and mounted on glass slides. Four sections were
sawed out of each bone-implant specimen; resulting in 16
sections per sheep and ultimately 128 sections overall [8].
Microtomographic scanning
The bone-implant specimens were scanned using a high
resolution mCT system (viva CT-40; Scanco Medical AG,
Bru¨ttisellen, Switzerland) using 70 kV energy and 85 mA
intensity [24]. All specimens were scanned using the same
scanning protocol settings and in the same orientation.
After mCT scanning, a volume of interest for each bone
specimen was defined as the concentric gap surrounding
the implant, i.e., starting from the surface of the titanium
alloy implant and ending at 2000 mm to the host bone. The
scanned images resulted in 3D reconstruction cubic voxel
sizes of 10.5  10.5  10.5 mm3 (2048  2048  2048 pixels).
An optimal global threshold of 200 was applied to segment
mCT images using the segmentation techniques described in
detail previously [25], with a slight modification to obtain
accurate 3D imaging datasets [26].
The following parameters were chosen for assessing
microarchitecture of the graft materials and bone within
the volume of interests after implantation: bone -
 substitute volume density [25], trabecular thickness
(TbTh) [27], structure model index (SMI) [28], and con-
nectivity density (CD) [29].
These microarchitectural parameters were chosen as
quantitative assessments of the bone regeneration within
the concentric gap. Bone substitute volume density de-
scribes the formation of bone. SMI characterises the 3D
structure types of the scaffold consisting of certain amount
of rods and plates. The value of SMI lies between 0 and 3,
when the structure consists of both rods and plates of equal
thickness, depending on the volume ratio of rods and
plates. An ideal plate-like structure will reflect a high me-
chanical strength and has a SMI value of 0, whereas an ideal
rod-like structure will reflect a low mechanical strength and
has a SMI value of 3 [28,30]. CD is a topological measure-
ment used to describe the number of multiple inter-
connected scaffold trabeculae within the material [29].
TbTh is also an important characteristic and directly related
to the mechanical strength of the bone-scaffold construct.
Histomorphometry
Stereological software (newCAST; Visiopharm, Denmark)
applying linear interception technique was used to quantify
tissue ingrowth at the titanium implant-material surface
[31]. The area fractions of bone, fibrous tissue, miscella-
neous, marrow, and substitute granules of the blinded
sections were quantified with the linear interception
technique. The area fraction of bone was quantified as “all
bone” (including allograft and new bone).
Table 1 Total number of fibroblastic colony forming units
obtained from the bone marrow aspirate of each sheep.
Sheep
no.
Total no. of
initial CFU-f
Meets the estimated
minimum no. of
CFU-f for bone
(5.200e7.500)
Braccini et al [17]
1 2241 No
2 33,024 OK
3 28,672 OK
4 6552 Minimum
5 322 No
6 35,872 OK
7 22,848 OK
8 992 No
CFU-f Z fibroblastic colony forming units.
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gap between the titanium implant and host bone was
quantified: Zone 1: from the titanium implant surface and
500 mm away into the grafted defect; and Zone 2: from
500e2000 mm into the grafted defect. The zones are
described in a current study by Babiker et al [32]. The vol-
ume fractions of bone, fibrous tissue, miscellaneous,
marrow, and substitute granules of the blinded sections
were quantified by point-counting technique [33]. The
sampling probe and size were defined in order to sample 100
“hits” for bone per implant site as previously described [23].
Mechanical testing
The bone specimens were thawed at room temperature 2
hours prior to mechanical testing. All specimens were
blinded and tested the same day under the same conditions
on an 858 Bionix MTS hydraulic material testing system (MTS
Systems Co., Minneapolis, MN, USA) using a 1kN load cell. A
preload of 2N defined the contact position for the test. The
implants were pushed out of the surrounding bone in the
direction of the implant axis. The displacement rate was
5 mm/minute. Load versus displacement data were recor-
ded and converted to stress and strain data to calculate
shear mechanical properties between implant and host
bonedshear stiffness (MPa), maximum shear strength
(MPa), and failure energy (kJ/cm2).
Statistical analysis
Results from mCT scanning were analysed with one-way
analysis of variance, following a post hoc Tukey’s test when
appropriate. Differences between group means were
considered statistically significant when p values were less
than 5%.
Data sets from mechanical testing and histo-
morphometry were not normally distributed; therefore,
differences between group medians were tested using
KruskaleWallis nonparametric analysis of variance by
ranks. All data from mechanical testing were presented
with the median indicated. For histomorphometric data,
median and interquartile ranges were given. Outliers were
excluded based on the Interquartile Method, where the
value s is an outlier if s < 1. Quartile - 1.5  interquartile
range or s > 3. Quartile þ 1.5  interquartile range. Dif-
ferences between group medians were considered statisti-
cally significant when p values were less than 5%.
The sample size calculation was based on previous
studies using histomorphometric and mechanical data for
the assessment of early implant fixation in large animal
models [34e36]. The number of sheep included in this study
was based on a sample size calculation, for a paired study
design:
nZðt2a þ tbÞ2SD
2
D2
ð1Þ
where a is the risk of a type I error and b is the risk of a type
II error. The critical value for 2a is 1.96 for a confidence
level of 95%. The critical value for b is 0.84, due to the
selected power (1-b) Z 80%. The minimal clinically rele-
vant difference, D is set to 70%. The standard deviation wasset to 50% for mechanical and histological data. Based on
the calculation above, at least six sheep per study should
be included in each study; thus, eight animals were
included for each scaffold material.
Results
No postoperative complications were seen, and all sheep
were able to stand or walk around approximately 2 hours
after surgery. No clinical signs of infections were observed
during the observation period of 6 weeks. One implant
(sheep 6) was loosened from the drilled defect during the
observation period; thus it was excluded from further an-
alyses. Outliers were also excluded from the push-out data.
Of the eight sheep, only five met the minimum number of
CFU-f for bone, and three CFU-f levels were too low [37].
The total amounts of CFU-fs are reported in Table 1.
3D microarchitecture
Microarchitectural analysis of bone formation in the
concentric gap revealed relatively less bone formation in
the granule þ BMA group than in the other groups, but this
was not statistically significant (Table 2). No significant
differences in the TbTh and CD were observed among the
four groups. The allograft had a more plate-like structure,
the granules, and BAG groups had a combination of plate
and rod structure, while the structure in the granule þ BMA
group was more rod-like (Table 2, Figure 1).
Histomorphometry
Tissue volume
Quantification of tissue volumes revealed a significantly
(p < 0.05) greater bone formation in the allograft group in
both Zones 1 and 2 than the other three groups, while there
were no significant differences among the other three
groups (Table 3). Furthermore, in Zone 2, the allograft
group had significant less fibrous tissue formation compared
with the other three groups (p < 0.05). The residual of
scaffold granules were not significantly different among the
three groups (Table 3).
Table 2 Microarchitectural parameters of bone (substitute) mass in concentric gap between implant and host bone for the
four groups.
BV/TV (%)a TbTh (mm)a SMI ()a CD ()a
Allograft (n Z 8) 44.3  10.0 67.6  7.9 0.3  1.5 867.1  148.7
Granules (n Z 8) 39.7  5.7 67.2  5.4 1.8  0.7 930.1  120.2
Granules þ BMA (n Z 7) 34.9  4.0 65.1  3.8 2.3  0.4 825.1  109.7
BAG (n Z 8) 45.0  11.8 98.8  84.1 1.2  1.3 930.2  188.2
p*
(ANOVA)
p Z 0.11 p Z 0.37 p < 0.009
Allograft < Granule þ BMA
p Z 0.44
ANOVA Z analysis of variance; BAG Z bioreactor activated graft material; BMA Z bone marrow aspirate; BV/TV Z bone  substitute
volume density; CD Z connectivity density; SMI Z structure model index; TbTh Z trabecular thickness.
* Differences between means were considered statistically significant for p values less than 0.05.
a Data are presented as mean  standard deviation.
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Histomorphometry revealed no significant differences be-
tween allograft and the other materials regarding ingrowth
(Table 4). The BAG seemed to induce less fibrous tissue at
the implantetissue interface as compared to the other
materials; however, this difference was not statistically
significant (Table 4).Histology
Histological observations of the tissueeimplant interface
supported the results from the histomorphometric analysesFigure 1 Three-dimensional reconstruction of micro-computed to
bone formation could be seen in the concentric gaps around the por
formed bone ingrowth to the porous surface of implant could also
BAG Z bioreactor activated graft material; BMA Z bone marrow aand push-out tests (Figure 2). Unresorbed scaffold granules
were seen in all slides, except for the allograft group.
Fibrous tissue encapsulation of the implant with minimal
bone formation was also seen.
Large amounts of bones, lamellar, and woven, were
observed in the allograft group, and the amounts of bone
seen in these specimens were largely concentrated in Zone
2. Similar observations were noticed for all other graft
material-bone tissue, and were largely seen in Zone 2.
Nonresorbed scaffold granules could be seen in all speci-
mens implanted with either granule alone, with BMA or as
BAG material. Ossicles were observed in specimens treated
with BAG material.mography images of four groups in the same sheep. Significant
ous surface of the titanium implant in all groups, and the newly
be observed, which determined mechanical fixation strength.
spirate.
Table 3 Histomorphometric analyses of tissue volumes, bone, fibrous tissue, and scaffold granules.
Tissue volume/total tissue (%) Bonea Fibrous tissuea Scaffold granulesa
Zone 1 Allograft (n Z 6) 28.3 (23.3e35.5) 21.0 (13.0e39.5) d
Granules (n Z 7) 13.0 (8.9e25.2) 52.3 (43.0e54.2) 19.9 (17.6e22.4)
Granules þ BMA (n Z 6) 7.2 (6.3e18.1) 42.0 (35.3e56.5) 24.4 (16.6e29.0)
BAG (n Z 7) 9.7 (7.5e13.1) 38.4 (37.2e51.1) 23.4 (21.1e26.7)
p*
(KruskaleWallis)
p < 0.05
Allograft > all
p Z 0.186 p Z 0.390
Zone 2 Allograft (n Z 6) 42.0 (35.2e44.5) 8.5 (2.7e12.7) d
Granules (n Z 7) 24.4 (22.3e26.9) 25.1 (18.3e35.0) 19.6 (13.0e24.0)
Granules þ BMA (n Z 6) 14.0 (5.5e23.7) 33.6 (23.3e39.4) 27.3 (18.6e32.4)
BAG (n Z 7) 12.1 (7.7e20.4) 37.7 (35.2e42.5) 24.6 (20.3e34.1)
p*
(KruskaleWallis)
p < 0.05
Allograft > all
p < 0.05
Allograft < all
p Z 0.362
BAG Z bioreactor activated graft material; BMA Z bone marrow aspirate.
* Differences between medians were considered statistically significant for p values less than 0.05.
a Data are presented as median (range).
Table 4 Histomorphometric analyses of tissue ingrowth to the porous surface of implant presented as a percentage of total
surface area: bone, fibrous tissue, and substitute.
Tissue ingrowth/total tissue (%) Bonea Fibrous tissuea Scaffold granulesa
Allograft (n Z 7) 18.8 (17.6e24.7) 75.0 (64.3e78.6) d
Granules (n Z 6) 20.5 (17.9e25.0) 73.0 (71.3e75.2) 0.2 (0.0e0.5)
Granules þ BMA (n Z 7) 28.8 (22.4e43.9) 70.2 (41.5e73.8) 0.2 (0.1e0.4)
BAG (n Z 7) 35.8 (19.4e43.4) 51.1 (48.3e58.56) 0.0 (0.0e1.0)
BAG Z bioreactor activated graft material; BMA Z bone marrow aspirate.
a Data are presented as [median (range)]. No significant differences between groups were observed.
Figure 2 Representative histology from implant pairs in the same sheep. (A) Allograft; (B) granules; (C) granules þ bone marrow
aspirate; and (D): bioreactor activated graft material. The white scale bar indicates 500 mm. Bo Z bone; Ft Z fibrous tissue;
Sc Z scaffold granules; Ti Z titanium alloy implant.
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Table 5 Mechanical push-out testing: stiffness, strength, and failure energy.
Stiffness (MPa)a Strength (MPa)a Failure energy (kJ/m2)a
Allograft (n Z 6) 0.28 (0.17e0.38) 0.06 (0.05e0.09) 16.0 (11.8e22.0)
Granules (n Z 7) 0.14 (0.11e0.21) 0.04 (0.03e0.09) 17.5 (9.20e24.2)
Granules þ BMA (n Z 6) 0.10 (0.08e0.14) 0.03 (0.02e0.04) 6.74 (5.70e7.71)
BAG (n Z 7) 0.09 (0.04e0.12) 0.02 (0.01e0.07) 7.71 (7.43e27.6)
p*
(KruskaleWallis)
p Z 0.096 p Z 0.383 p Z 0.334
BAG Z bioreactor activated graft material; BMA Z bone marrow aspirate.
* No significant differences between groups were observed.
a Data are presented as median (range).
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The results from the mechanical push-out test (Table 5)
showed no significant differences between groups regarding
shear stiffness, maximum shear strength, and failure
energy.
Discussion
The ideal bone substitute for fixation of larger implants
should hold several characteristics including osteo-
conductivity, osteoinductivity, and osteogenicity. Osteo-
conductivity ensures the guiding of new bone growth and
ultimately assures mechanical stability. Osteoinductivity
can be obtained by adding cells with osteogenic potential
such as BMSC. The concept of a joint incubation of BMSC
and a porous ceramic scaffold for creation of a bone sub-
stitute with the above-mentioned properties has been
proved [38,39]. However, a large-scale production of viable
bone substitutes in a perfusion bioreactor for implantation
in critically sized defects has to our knowledge not yet been
tried. This study aimed at producing large viable bone
grafts activated in a perfusion bioreactor for early implant
fixation. This study used a large sheep model with bone
properties similar to human bone [40], and allowed us to
compare four different groups of materials in each animal;
thus, minimising biological variation between animals [8].
The results of this study revealed that bioreactor activated
graft material did not convincingly induce early bone for-
mation similar to allograft, although nice early bone for-
mation and implant fixation were observed in all groups.
The fabrication of scaffold granules used in this study
was designed to bear porosities and interconnected pore
sizes that are highly compatible with bone ingrowth [41].
Hence, new bone formation could be observed within the
pores of the scaffold granules as visualised with histology.
The coating of scaffold granules with PLA is not assumed to
have a negative effect on bone formation, as PLA has been
used as a biomaterial for many years. We have recently
demonstrated that excellent bone formation in the
combining PLA coated scaffold granules with BMSC incu-
bated in a perfusion bioreactor [8].
Living cells with proliferative potential were prerequi-
site for activation of the scaffold granules. The total
numbers of CFU-fs from BMA in five sheep had reached the
suggested minimum level for bone formation, while three
sheep did not. The bone formation in the concentric gap inthese sheep was not significantly different compared with
the other animals. Unlike in vitro conditions where the
culture environment was well-controlled, the in vivo envi-
ronment was far more complicated, e.g., bone formation
could be influenced by blood supply, cells, and growth
factors released from the host bone etc. Thus, it is likely
that CFU-fs may not be the only factor predicting bone
formation in vivo.
Microarchitectural analysis revealed that bone forma-
tions in the allograft and the BAG groups were significantly
greater compared with the granule þ BMA group. Thus,
adding BMA to substitute did not show any additional pos-
itive effect on bone formation. Furthermore, the structure
of the allograft group was typically plate-like, and the
structures of the other three groups were more rod-like or
combination of plate and rod. This newly formed bone
tissues within the gap (mainly woven bone) might take
some time to remodel to become lamellar bone. The TbTh
and the connectivity were not different among the four
groups.
The microarchitectural parameters of the implanted
graft materials largely supported the findings from histo-
morphometry regarding bone formation. The results for
bone formation as evaluated by histomorphometry were
separated in two zones, whereas the results from micro-
architectural analysis did not discriminate between zones.
Implanting allograft still resulted in a higher formation of
bone. When comparing the three substitute groups, the
granule þ BMA group was lowest in bone formation by
microarchitectural analysis. By histomorphometry, the
bone formation in the granule þ BMA group was signifi-
cantly lower than in the allograft, but not statistically
different compared with the other two granule groups. A
previous study at our research laboratory has shown that
biopolymer coating alters the mechanical and structural
properties of a mineral scaffold [21].
For the PDLLA-reinforced scaffold granules, push-out
tests showed no significant differences between groups.
This finding was supported by the histomorphometric re-
sults assessing ingrowth at the tissueeimplant interphase.
The formation of fibrous tissue in the gap was prominent for
all graft materials, whereas bone formation only counted
for approximately 20e30%. The bioreactor activated graft
material as well as granules with BMA induced more bone
and less fibrous tissue formation than seen with the other
two graft materials. This difference is, however, not sta-
tistically significant.
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assumed to have a negative effect on bone formation, as
PDLLA have been used as a biomaterial for years. Recent
published data from our research laboratory show bone
formation combining PDLLA coated scaffold granules with
BMSC incubated in a perfusion bioreactor [42]. However, a
study has shown delayed osteoinduction and, therefore,
less bone formation on composite PDLLA coated scaffolds
consisting of HA/b-TCP [43]. The scaffold granules were
infiltrated with PDLLA in order to increase the mechanical
strength of the material. This was done without compro-
mising the microarchitecture of the scaffold granules [21];
thus, preserving the osteoinductive potential of the scaf-
fold granules. Even though the scaffold materials were not
tested against each other, no differences between the
properties of the implanted scaffold granules could be
concluded; thus, a PDLLA coated scaffold material could be
an interesting alternative to allograft for implantation in
weight bearing areas.
The remodelling phases of the implanted allograft were
examined using histology, and were in full accordance with
the results from histomorphometry. Several limitations
need to be pointed out.
Firstly, the embedment technique and preparation of
the slides for histomorphometry resulted in several arte-
facts in the tissue. This was especially evident for the
groups treated with scaffold granules. The nonresorbed
granules were very loosely fitted in the tissue and loosening
granules might have resulted in loosening of the adjacent
tissues. Therefore, the tissue fractions quantified with mCT
scanning are probably more unbiased and closer to the true
values. Secondly, like all other preclinical animal studies,
the results should be interpreted with caution, and a
relatively small sample size might also compromise the
significance of the investigation. Nevertheless, the strength
of this study was the pair design that compared four scaf-
fold granules within each animal minimising biological
variations commonly seen in animal studies, and a novel
bioreactor was used to assess the hypothesis that biore-
actor might promote bone formation and implant fixation.
Bioreactor incubation of scaffold granules with BMSC did
not result in significantly more bone formation than gran-
ules implanted with no cells. This gives reason to speculate
that bioreactor activation is redundant, and that the design
and ultimately osteoinductive properties of the scaffold
used, is imperative for early bone induction and integration
in as proposed by other studies [44,45].Conclusion
In summary, this study did not support the hypothesis that
the BAG could enhance early bone formation in a critically
sized defect in sheep. Although bone formation in the gap
in the allograft group was significantly greater than in the
other three substitute groups, the bone ingrowth into the
porous titanium implant was not different, nor the shear
mechanical properties. Taken together, BAG did not
convincingly induce early implant fixation similar to allo-
graft. This study suggests that neither bioreactor nor by
adding BMA credited additional benefit for bone formation
in this model.Conflicts of interest
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